MNTA Momenta Pharmaceuticals Inc

Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA), a biotechnology company focused on discovering and developing novel biologic therapeutics to treat rare immune-mediated diseases, today announced that it will release its financial results for the second quarter ended June 30, 2020 before the U.S. financial markets open on Monday, August 10, 2020.

Management will host a conference call on August 10, 2020 at 8:30 a.m. ET to discuss these results and provide an update on the Company. Investors and participants can register for the call in advance by visiting http://dpregister.com/10146816. Upon registering, each participant will be provided with call details and a registrant ID. Alternatively, the conference call will be available via a live webcast. To access the live webcast or the replay, visit the Company's website www.momentapharma.com and click on the Investors and News tab.

If you are unable to pre-register, please join by dial-in by calling (888) 349-0106 (domestic) or (412) 902-0131 (international)  prior to the scheduled conference call time and provide the access code 9178486.

An archived version of the webcast will be posted approximately two hours after the call.

About Momenta Momenta Pharmaceuticals is a biotechnology company with a validated innovative scientific platform focused on discovering and developing novel therapeutics to treat rare, immune-mediated diseases and advancing its late stage biosimilar portfolio. The company is headquartered in Cambridge, MA.

To learn more about Momenta, please visit www.momentapharma.com, which does not form a part of this press release.

Momenta’s logo, trademarks, and service marks are the property of Momenta Pharmaceuticals, Inc. All other trade names, trademarks, or service marks are property of their respective owners.

Forward-Looking Statements 

Statements in this press release regarding management's future expectations, beliefs, intentions, goals, strategies, plans or prospects, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including but not limited to statements about the use, design, timing, strategy and goals of clinical trials; the efficacy, safety, tolerability, potency, convenience and commercial potential of our product candidates, and the timing of the announcement of its financial results for the quarter ended June 30, 2020. Forward-looking statements may be identified by words such as "believe," "continue," "plan to," "potential," "will," and other similar words or expressions, or the negative of these words or similar words or expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other important factors, including the risk of the unpredictable nature of early stage development efforts for our product candidates; safety, efficacy or tolerability problems with our product candidates; unexpected adverse clinical trial results; and those referred to under the section "Risk Factors" in the Company's Annual Report on Form 10-Q for the quarter ended March 31, 2020 filed with the Securities and Exchange Commission, as well as other documents that may be filed by the Company from time to time with the Securities and Exchange Commission. As a result of such risks, uncertainties and factors, the Company's actual results may differ materially from any future results, performance or achievements discussed in or implied by the forward-looking statements contained herein. The Company is providing the information in this press release as of this date and assumes no obligations to update the information included in this press release or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

INVESTOR CONTACT:Patty EisenhaurMomenta Pharmaceuticals1-617-395-5189IR@momentapharma.com